India Silent Heart Attack Market Trends, Growth, Opportunities and Forecast 2022-2028

 

India silent heart attack market is estimated to grow modestly at a CAGR of around 9.1% during the forecast period. The country is one of the emerging economies globally leading to an increase in healthcare expenditure. Due to the rising disposable income, the expenditure on healthcare services has increased substantially in the country. The government is actively focused on improving healthcare infrastructure in the country due to the growing number of chronic diseases including CVDs. For instance, the Indian government has launched Ayushman Bharat, the world’s largest government-funded scheme in September 2018. It is a health premium program focused on providing affordable and better healthcare services to the people of the country. Moreover, the availability of advanced treatment options in India with the increasing per capita healthcare expenditure is supporting the growth of the silent heart attack market in the country.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/india-silent-heart-attack-market

India silent heart attack market is segmented into diagnosis, treatment, and end-user. Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest x-ray, computed tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics and ambulatory surgical centers (ASCs). Surgery is most commonly required to increase blood flow through a blocked artery. Therefore, angioplasty and bypass surgery are significantly used for the management of blocked arteries and improve blood flow to the heart.

The companies which are contributing to the growth of the India silent heart attack market include AstraZeneca PLC, Bayer AG, GlaxoSmithKline PLC, Pfizer Inc., SLTL Group, and Terumo Corp. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

India Silent Heart Attack Market- Segmentation

By Diagnosis     

·         Electrocardiography (ECG)

·         Magnetic Resonance Imaging (MRI)

·         Computed Tomography (CT Scan)

·         Echocardiography

·         Others (Blood Test)

By Treatment   

·         Medication

·         Surgery

·         By End-User

·         Hospital & Clinics

·         Ambulatory Surgical Centers

A full report of India Silent Heart Attack Market is available at: https://www.omrglobal.com/industry-reports/india-silent-heart-attack-market

Company Profiles

·         Astellas Pharma Inc.

·         AstraZeneca PLC

·         Bayer AG

·         Boehringer Ingelheim GmbH

·         Boston Scientific Corp.

·         F. Hoffmann-La Roche Ltd.

·         GlaxoSmithKline Plc

·         Medtronic PLC

·         Novartis AG

·         Opto Circuits Ltd.

·         Pfizer Inc.

·         Siemens AG

·         SLTL Group

·         Takeda Pharmaceutical Co. Ltd.

Reasons to Buying From us –

1.       We cover more than 15 major industries, further segmented into more than 90 sectors.

2.       More than 120 countries are for analysis.

3.       Over 100+ paid data sources mined for investigation.

4.       Our expert research analysts answer all your questions before and after purchasing your report.

 

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

 

Media Contact:

Contact Person: Mr. Anurag Tiwari

Email: anurag@omrglobal.com

Contact no: +91 780-304-0404

Company Name: Orion Market Research